Baxter touts study indicating cost savings with Revaclear dialyzer

Baxter (NYSE:BAX) today released results from a study of its Revaclear high-flux dialyzer, touting lower use of erythropoiesis-stimulating agent with the filter.

Use of the Revaclear dialyzer was associated with 100 to 600 fewer units of ESA used per hemodialysis session when compared against Optiflux 160 or Optiflux 180 dialyzers, Deerfield, Ill.-based Baxter said.

”Maintaining hemoglobin levels using the lowest doses of ESA as possible in this patient population is important in preventing many cardiovascular complications and maintaining adequate energy levels. This study suggests that clinicians may be able to reduce patient exposure to ESAs without sacrificing hemoglobin levels,” study author Dr. Maggie Gellens said in a press release.

Decreasing ESA use by an average dose of 275 units would mean potential savings of $4.39 per hemodialysis session, according to the report, which comes out to $660 savings per patient per year at 3 dialysis sessions a week.

”Reducing the cost of one hemodialysis session can be significant considering that more than 60 million hemodialysis sessions are delivered in the U.S. annually,” Baxter global HEOR senior director Suzanne Laplante said in prepared remarks.

Results from the study were published online in the American Society for Artificial Internal Organs Journal, Baxter said.

The retrospective, propensity matched study aimed to examine comparative effectiveness of commonly used dialyzers in the U.S. and analyzed 37,500 patient records for 12 months post-hemodialysis use with one of the dialyzers included in the study, Baxter said.

Late last month, Baxter said it won a nod north of the border for its Amia automated peritoneal dialysis system.

The Health Canada approval makes Amia the 1st automated peritoneal dialysis device cleared in the U.S. and Canada that includes voice guidance, touchscreen control and 2-way telemedicine features, Baxter said.

Baxter said it plans to start a pilot launch of the Amia device in Canada late this year. The device won 510(k) clearance from the FDA in October 2015.

The post Baxter touts study indicating cost savings with Revaclear dialyzer appeared first on MassDevice.

from MassDevice http://ift.tt/2ai5yjz